Your doctor has chosen this medicine to suit you and your condition. Seretide is used to help with breathing problems in people who need regular treatment.
It is very important that you use your Seretide every day, as instructed by your doctor. This will help you to keep free of symptoms throughout the day and night.
Seretide should not be used to relieve a sudden attack of breathlessness or wheezing.
If you get this sort of attack you must use a quick acting inhaler (eg. Ventolin) also known as a reliever puffer.
If you feel you are getting breathless or wheezy more often than normal, or you are using your reliever inhaler more than usual, you should go to your doctor.
Is your asthma under control? Take the Asthma Control Test™
Seretide® (fluticasone propionate/salmeterol xinafoate; available as a 50/25 or 125/25 micrograms per actuation inhaler, or as a 100/50 or 250/50 micrograms per actuation Accuhaler®) is a Prescription Medicine for the treatment of reversible obstructive airway disease (ROAD) including asthma, and for the treatment of chronic obstructive pulmonary disease (COPD). Seretide is a fully funded medicine; Special Authority criteria apply. Seretide 250/25 microgram inhaler is a private purchase medicine that you will need to pay for. Use strictly as directed. Seretide is not for relief of acute symptoms. Always carry your reliever inhaler. Do not discontinue Seretide abruptly. Tell your doctor if: you are taking any other medicines or herbal remedies; you have pulmonary tuberculosis (TB), a thyroid problem or a heart problem; or you are having treatment for high blood pressure; Side Effe cts may include: 'shaky' feeling; headache; fast heart rate; irritation in the nose and throat. If symptoms continue or you have side effects, see your doctor, pharmacist or health professional. For more information, see Seretide Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor's office visit fees apply. Ask your doctor if Seretide is right for you.
Seretide and Accuhaler are registered trade marks of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. TAPS No. DA4412QL/12MA/084